Skip to content

AIM round-up: Mobilityone, Braveheart Investment, Jet2


The junior market had another difficult day, reversing more than ten points and making for the worst performance since early October, reaching the bell at 1236.29

  • Mobilityone +32%
  • Braveheart Investment Group +25%
  • Abingdon Health -20%
  • Agriterra -14%
  • Jet2 -10%

Mobilityone LON:MBO topped the board today, with the Malaysian mobile payments company adding 32% by the bell. Shares in the company have been under marked pressure since the summer, making today’s rebound even more notable. Transactions have however been rather lumpy and gains are tempered by the fact a closing spread of 10% was being quoted.

Braveheart Investment Group LON:BRH also saw a solid performance on Thursday, with shares advancing 25% by the bell. There’s no new news here formally, but at the start of the week the company published interim results which made for impressive reading. There are also suggestions that a portfolio company may have made a good step forward in terms of product distribution.

Abingdon Health LON:ABDX was the day’s laggard, off almost 20% by 4.30pm. The stock topped the board yesterday but evidently today’s preliminary results fell short of expectations for some, despite the company’s belief that lateral flow tests can prove to be a powerful diagnostic tool going forward.

Agriterra LON:AGTA also languished, with the £1m minnow of a stock sitting some 14% lower by the close. Given the very limited trade and the fact the closing spread is sitting around 30% however, there’s arguably little to worry about here.

A notable mention for Jet2 LON:JET2, whose shares have been under pressure for the last couple of weeks but tacked on a further 10% decline today. The company published interims this morning but despite highlights including the fact that planned capacity for summer 2022 is 13% higher than was seen in summer 2019, the market evidently took the glass-half-empty view. The lack of forward visibility across the travel sector, combined with the reintroduction of COVID restrictions across parts of Europe, is perhaps understandably frustrating, but pushing the stock close to 12 month lows could be seen as overblown.

Looking for great investing ideas? Sign up to our free newsletter.

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

CME Group
FP Markets
Back To Top